Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Parliament Wants Two-Tier Database To Monitor Drug Supplies

Coordinated Clinical Trials Also Important

Executive Summary

High-level negotiations are due to begin later this month on a draft regulation that will give the European Medicines Agency new powers to tackle supply chain issues amid health emergencies.

You may also be interested in...



EU Politicians Want Stronger Role For European Medicines Agency In Health Risk Assessment

Legislation that will help to build a future “European Health Union” is making its way through the EU legislative process. It includes a greater role for EU health agencies in making preparations for future health emergencies.

Coronavirus Notebook: EMA Explains How To Get A Modified Vaccine Approved, UK Starts Oxford/AZ Variant Vaccine Trial

Draft legislation on strengthening the European Medicines Agency’s role in health crises has cleared another hurdle, and the European Commission is inviting companies to a matchmaking event aimed at scaling up the development and production of COVID-19 therapeutics.

Major Review Of EU Pharmaceutical Legislation Kicks Off

The European Commission has launched the process for reshaping and addressing the long-standing weakness in the EU’s pharmaceutical legislation. It has listed in a roadmap the issues it wants to address as it considers policy options for reforms.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS144608

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel